Follow
Yuanbing JIANG
Yuanbing JIANG
Verified email at connect.ust.hk
Title
Cited by
Cited by
Year
Large‐scale plasma proteomic profiling identifies a high‐performance biomarker panel for Alzheimer's disease screening and staging
Y Jiang, X Zhou, FC Ip, P Chan, Y Chen, NCH Lai, K Cheung, RMN Lo, ...
Alzheimer's & Dementia 18 (1), 88-102, 2022
742022
Genetic and polygenic risk score analysis for Alzheimer's disease in the Chinese population
X Zhou, Y Chen, FCF Ip, NCH Lai, YYT Li, Y Jiang, H Zhong, Y Chen, ...
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 12 (1 …, 2020
262020
Deep learning-based polygenic risk analysis for Alzheimer’s disease prediction
X Zhou, Y Chen, FCF Ip, Y Jiang, H Cao, G Lv, H Zhong, J Chen, T Ye, ...
Communications Medicine 3 (1), 49, 2023
142023
An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer’s disease
Y Jiang, X Zhou, HY Wong, L Ouyang, FCF Ip, VMN Chau, SF Lau, W Wu, ...
Nature aging 2 (7), 616-634, 2022
142022
The VCAM1–ApoE pathway directs microglial chemotaxis and alleviates Alzheimer’s disease pathology
SF Lau, W Wu, HY Wong, L Ouyang, Y Qiao, J Xu, JHY Lau, C Wong, ...
Nature Aging 3 (10), 1219-1236, 2023
112023
Blood transcriptome analysis for Alzheimer’disease in Hong Kong Chinese population
H Zhong, X Zhou, Y Jiang, Y Chen, NCH Lai, EPS Tong, RMN Lo, ...
Alzheimer's & Dementia 17, e056643, 2021
22021
Deep learning methods improve polygenic risk analysis and prediction for Alzheimer’s disease
X Zhou, Y Chen, F Ip, Y Jiang, H Cao, H Zhong, J Chen, T Ye, Y Chen, ...
Commun. Med.(Lond) 3, 49, 2021
22021
Using deep learning models to examine the biological impact of polygenic risks for Alzheimer’s disease
X Zhou, FCF Ip, G Lv, Y JIANG, H Cao, H Zhong, L Chen, AKY Fu, NY Ip
Alzheimer's & Dementia 19, e065377, 2023
12023
Using blood transcriptome analysis for Alzheimer's disease diagnosis and patient stratification
H Zhong, X Zhou, H Uhm, Y Jiang, H Cao, Y Chen, TTW Mak, RMN Lo, ...
Alzheimer's & Dementia, 2024
2024
A blood‐based multi‐pathway biomarker assay for early detection and staging of Alzheimer's disease across ethnic groups
Y Jiang, H Uhm, FC Ip, L Ouyang, RMN Lo, EYL Cheng, X Cao, CMC Tan, ...
Alzheimer's & Dementia, 2024
2024
Protein markers for assessing alzheimer's disease
NY Ip, KY Fu, Y JIANG, Z Xiaopu, FCF Ip
US Patent App. 17/996,498, 2023
2023
An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE‐ε4 in Alzheimer’s disease
Y JIANG, X Zhou, HY Wong, O Li, FCF Ip, VMN Chau, SF Lau, W Wu, ...
Alzheimer's & Dementia 19, e064428, 2023
2023
An IL1RL1 genetic variant lowers soluble ST2 levels and attenuates the impact of APOE-ε4 in Alzheimer's disease
Y Jiang, X Zhou, HY Wong, L Ouyang, FCF Ip, MN Chau, SF Lau, W Wu, ...
2022
A high‐performance biomarker panel for Alzheimer’s disease screening and staging identified by large‐scale plasma proteomic profiling
Y Jiang, X Zhou, FCF Ip, P Chan, Y Chen, NCH Lai, K Cheung, RMN Lo, ...
Alzheimer's & Dementia 17, e056099, 2021
2021
Deep learning for polygenic score analysis for Alzheimer’s disease risk prediction in the Chinese population
X Zhou, Y Chen, FCF Ip, Y Jiang, H Cao, H Zhong, Y Chen, J Chen, ...
Alzheimer's & Dementia 17, e056625, 2021
2021
Genetic variants for diagnosis of alzheimer's disease
NYYCHU IP, KY Fu, Z Xiaopu, Y JIANG, Y Chen, FCF Ip
2021
Deregulation of IL-33/ST2 signaling in Alzheimer’s disease
Y Jiang, X Zhou, Y Wang, NCH Lai, PS Tong, VCT Mok, TCY Kwok, ...
2019
An IL1RL1 genetic variant lowers soluble ST2 levels and the risk genetic variant lowers soluble ST2 levels and the risk effects of effects of APOE-ɛ4 in female patients with …
Y Jiang, X Zhou, HY Wong, L Ouyang, FCF Ip
An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ɛ4 in female patients with Alzheimer’s disease effects of APOE-4 in female patients with …
Y Jiang, X Zhou, HY Wong, L Ouyang, FCF Ip
The system can't perform the operation now. Try again later.
Articles 1–19